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Objective. Juvenile dermatomyositis (DM) is a heterogeneous systemic immune- mediated vasculopathy. This 
study was undertaken to 1) identify inflammation/endothelial dysfunction–related biomarker profiles reflecting disease 
severity at diagnosis, and 2) establish whether such biomarker profiles could be used for predicting the response to 
treatment in patients with juvenile DM.
Methods. In total, 39 biomarkers related to activation of endothelial cells, endothelial dysfunction, and inflammation 
were measured using multiplex technology in serum samples from treatment- naive patients with juvenile DM from 2 
independent cohorts (n = 30 and n = 29). Data were analyzed by unsupervised hierarchical clustering, nonparametric 
tests with correction for multiple comparisons, and Kaplan- Meier tests with Cox proportional hazards models for 
analysis of treatment duration. Myositis- specific antibodies (MSAs) were measured in the patients’ serum using line 
blot assays.
Results. Severe vasculopathy in patients with juvenile DM was associated with low serum levels of intercellular 
adhesion molecule 1 (Spearman’s rho [rs] = 0.465, P = 0.0111) and high serum levels of endoglin (rs = −0.67, 
P < 0.0001). In the discovery cohort, unsupervised hierarchical clustering analysis of the biomarker profiles yielded 2 
distinct patient clusters, of which the smaller cluster (cluster 1; n = 8) exhibited high serum levels of CXCL13, CCL19, 
galectin- 9, CXCL10, tumor necrosis factor receptor type II (TNFRII), and galectin- 1 (false discovery rate <0.0001), 
and this cluster had greater severity of muscle disease and global disease activity (each P < 0.05 versus cluster 
2). In the validation cohort, correlations between the serum levels of galectin- 9, CXCL10, TNFRII, and galectin- 1 
and the severity of global disease activity were confirmed (rs = 0.40–0.52, P < 0.05). Stratification of patients 
according to the 4 confirmed biomarkers identified a cluster of patients with severe symptoms (comprising 64.7% of 
patients) who were considered at high risk of requiring more intensive treatment in the first 3 months after diagnosis  
(P = 0.0437 versus other cluster). Moreover, high serum levels of galectin- 9, CXCL10, and TNFRII were predictive of 
a longer total treatment duration (P < 0.05). The biomarker- based clusters were not evidently correlated with patients’ 
MSA serotypes.
Conclusion. Results of this study confirm the heterogeneity of new- onset juvenile DM based on serum biomarker 
profiles. Patients with high serum levels of galectin- 9, CXCL10, TNFRII, and galectin- 1 may respond suboptimally to 
conventional treatment, and may therefore benefit from more intensive monitoring and/or treatment.
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INTRODUCTION
Juvenile dermatomyositis (DM) is a rare systemic immune- 
mediated disease with an incidence of 2–4 cases per million per 
year (1). The clinical presentation is heterogeneous, as patients 
can develop a spectrum of symptoms, ranging from the typical 
symptoms of proximal skeletal muscle weakness and pathogno-
monic skin rash, to involvement of vital organs such as the lungs, 
heart, brain, and intestines (2). The clinical heterogeneity of juvenile 
DM has been linked to myositis- specific autoantibodies (MSAs), 
the levels of which may distinguish distinct clinical phenotypes 
and could be prognostic for the disease course and the need for 
second- line therapy (3). Despite this disease heterogeneity, cur-
rent treatment guidelines are not yet adapted to subgroup- specific 
needs (4). Stratification of patients, e.g., into high- risk or low- risk 
groups, may facilitate the development of personalized monitoring 
and treatment strategies.
In addition to inflammation of the muscles and skin, vascu-
lopathy is an important hallmark of juvenile DM (5,6). The disease 
is characterized by a loss of capillaries, morphologic changes to 
the endothelium, endothelial cell activation, and small vessel angi-
opathy (5–8). Complement and immune complexes are involved 
in its pathogenesis, but a disturbed balance between angiostatic 
and angiogenic factors also plays a role (9–11). The degree of 
vasculopathy is correlated with the expression of interferon (IFN)–
inducible angiostatic chemokines (11), indicating that vascular 
injury may be related to the IFN signature (5). This IFN signature 
has been identified in the serum and many cell types, including 
endothelial cells, from patients with juvenile DM (11–17).
The degree of vasculopathy is clinically relevant: pathologic 
changes in nailfold capillaries are associated with clinical disease 
activity (18), and prominent vascular injury evident in muscle biopsy 
tissue was found to be associated with severe clinical presentation 
and outcomes (19,20). Recently, Gitiaux et al identified a subgroup 
of juvenile DM patients with severe disease, based on trajectories 
of clinical parameters during follow- up (19). Juvenile DM in these 
patients was characterized by severe muscle weakness, frequent 
limb edema, gastrointestinal involvement, higher myopathologic 
scores (e.g., capillary dropout), and low remission rates (19). Most 
of these manifestations could be related to vasculopathy (19).
Herein we used a minimally invasive biomarker- based 
approach to identify juvenile DM patients, both from a discovery 
cohort and from an independent validation cohort, who had a 
severe disease course already present at diagnosis. The biomarker 
panel analyzed included previously described and novel mark-
ers related to endothelial cell activation, endothelial dysfunction, 
and IFN- driven inflammation (5,17). Specifically, we investigated 
whether biomarker profiles were linked to vasculopathy, disease 
severity, and frequency of MSA subtypes, and whether the levels 
of these biomarkers might be predictive of the response to induc-
tion therapy and the time required to attain drug- free remission 
(DFR).
PATIENTS AND METHODS
Participants. For this study, 59 patients meeting the Bohan 
and Peter criteria for definite or probable juvenile DM (21,22), from 
Chicago, Illinois for the discovery cohort (n = 30) and from Utrecht, 
The Netherlands and Singapore for the validation cohort (n = 25 
and n = 4), were included before the start of treatment, between 
March 2004 and June 2018. Scores on the Childhood Myositis 
Assessment Scale (CMAS) (scale 0–52, or scale 0–49 for ages 4–5 
years) (23) were recorded in both cohorts as a measure of mus-
cle disease activity. Disease Activity Scores (DAS) for the muscle 
(DAS- M) (scale 0–11) and skin (DAS- S) (scale 0–9), and global 
DAS for total disease activity (DAS- T) (scale 0–20) were recorded 
in the discovery cohort (24), while in the validation cohort, the phy-
sician’s global assessment of disease activity (PhGA) (scale 0–10) 
(25) and the cutaneous assessment tool (CAT) for juvenile DM 
(scale 0–116) (26) were used.
Intensification of treatment was defined as the addition of 
new immunosuppressive medication or an increase in the dose 
of a previous medication. Time to attainment of DFR was defined 
as the time (in months) between the date at the start of immu-
nosuppressive treatment and the date at the time of withdrawal 
of all immunosuppressive drugs. In the discovery cohort, treat-
ment regimens were individualized, while in the validation cohort, 
treatment regimens were based on the SHARE (Single Hub 
and Access point for pediatric Rheumatology in Europe)   
recommendations (4).
End row loops (ERLs), as a proxy for the severity of vascu-
lopathy (27), were assessed by nailfold capillaroscopy. Standard-
ized digital nailfold images from 8 fingers, excluding the thumbs, 
were obtained, and findings were analyzed by counting the 
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ERLs in a 3- mm segment, yielding the average count of ERLs/
mm. The lower limit of normal for this value is 7 ERLs/mm (inter-
quartile range 7.61–8.94), as previously reported (27). To define 
severe vasculopathy, a cutoff ERL score of <4 was used, based 
on the median value for all abnormal ERL scores in the cohort 
(abnormal ERL defined as a score of <7; n = 27). ERLs were only 
assessed in the discovery cohort.
In addition, serum samples from all patients were assessed 
for the frequency of MSAs. Serum MSAs were measured by line 
blot assay (Euroimmun DL 1530- 1601- 4 G/5001- 4 G/6401- 4 G).
This study was approved by the institutional ethics com - 
mittees of the involved centers: the UMC Utrecht (METC 
approval no. 15- 191), the SingHealth centralized Institutional 
Review Board (IRB) (CIRB approval no. 2014/083/E), and the 
Table 1. Baseline characteristics of the juvenile dermatomyositis patients from the discovery and validation cohorts*
Discovery cohort 
(Chicago, IL) 
(n = 30)
Validation cohort 
(Netherlands and Singapore) 
(n = 25 and n = 4) P
Age at sampling, median (IQR) years 5.1 (3.7–8.6) 7 (3.9–12.1) 0.192
Sex, no. (%) female 26 (86.7) 18 (62.1) 0.039
Ethnicity, % white/Hispanic/African American/Asian 77/20/3/0 76/0/10/14 0.012
Duration of untreated disease, median (IQR) months 5.9 (3.6–14.8) 3.2 (1.4–9.1) 0.020
Intensification of treatment in first 3 months, no. (%) 17 (56.7) 8 (28.6) 0.038
Disease activity at diagnosis
CMAS (scale 0–52 or 0–49 for ages 4–5 years), median (IQR) 33 (23.5– 44)† 33 (15– 40.5)‡ 0.334
PhGA, median (IQR) (scale 0–10) – 5.8 (4.0–7.7)‡ NA
DAS total, median (IQR) (scale 0–20) 12 (9.4–13.3) – NA
DAS muscle, median (IQR) (scale 0–11) 6 (3.8–8) – NA
DAS skin, median (IQR) (scale 0–9) 5 (5–6.3) – NA
CAT score, median (IQR) (scale 0–116) – 5 (3.5–11) NA
Muscle enzyme levels at diagnosis, median (IQR) IU/liter
CK 131 (88–680) 510 (138–4,357) 0.053
LDH 364 (270–460)† 497 (358–837)‡ 0.010
AST 46 (35–80) 65 (41–307)§ 0.118
ALT 26 (17–43)† 45 (23–112) 0.158
Myositis- specific antibodies, no. (%)
Negative 14 (46.7) 16 (55.2) 0.800
MDA- 5 2 (6.7) 2 (6.9) 1.000
Mi- 2 3 (10) 0 (0) 0.237
NXP- 2 
Total 2 (6.7) 5 (17.2) 0.254
Strongly positive 1 (3.3) 3 (10.3)
Weakly positive 1 (3.3) 2 (6.9)
SAE- 1 0 (0) 2 (6.9) 0.237
TIF-­1γ
Total 9 (30.0) 4 (13.8) 0.209
TIF-­1γ­only 8 (26.7) 3 (10.3)
TIF-­1γ­+­PL-­7 0 (0) 1 (3.4)
TIF-­1γ­+­PL-­12 1 (3.3) 0 (0)
Initial therapy after diagnosis, no. (%)
Oral Pred. 1 (3.3) 0 (0.0) 1.000
MTX­+­oral­Pred. 2 (6.7) 0 (0.0) 0.492
IVMP­+­oral­Pred. 1 (3.3) 1 (3.4) 1.000
IVMP­+­oral­Pred.­+­MTX 19 (63.3) 20 (69.0) 0.7847
IVMP­+­oral­Pred.­+­IVIG 0 (0.0) 1 (3.4) 0.492
IVMP­+­oral­Pred.­+­MTX­+­IVIG 1 (3.3) 0 (0.0) 1.000
IVMP­+­oral­Pred.­+­MTX­+­HCQ 6 (20.0) 7 (24.1) 0.761
* P values were calculated by Mann- Whitney U test for continuous variables, and by Fisher’s exact test for categorical variables 
(comparisons of 2 categories) or chi- square test (comparisons of >2 categories). Myositis- specific antibodies were measured by line 
blot assay. Normalization of muscle enzyme levels to the age- and center- specific upper limits of normal did not change the results. 
IQR = interquartile range; CMAS = Childhood Myositis Assessment Scale; PhGA = physician’s global assessment of disease activity; 
NA = not applicable; DAS = Disease Activity Score; CAT = cutaneous assessment tool (for juvenile dermatomyositis); CK = creatine 
kinase; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; MDA- 5 = melanoma 
differentiation–associated protein; NXP- 2 = nuclear matrix protein 2; SAE- 1 = small ubiquitin- like modifier- 1 activating enzyme; 
TIF- 1γ = transcription intermediary factor 1γ; Pred. = prednisone; MTX = methotrexate; IVMP = intravenous methylprednisolone; 
IVIG = intravenous immunoglobulin; HCQ = hydroxychloroquine. 
† Data not reported for 1 patient. 
‡ Data not reported for 4 patients. 
§ Data not reported for 2 patients. 
WIENKE ET AL 4       |
Ann & Robert H. Lurie  Children’s Hospital of Chicago (IRB 
approval nos. 2001- 11715 and 2010- 14117). The study was 
conducted in patients in accordance with the Declaration of Hel-
sinki. Age- appropriate written informed consent was obtained 
prior to inclusion of each patient in the study.
Analysis of a biomarker panel in patients’ serum. 
Serum was spun down and stored at −80°C within 4 hours after 
collection. In total, 39 biomarkers related to endothelial cell acti-
vation, endothelial dysfunction, and inflammation were simulta-
neously measured using multiplex technology (xMAP; Luminex) 
in 50 μl of serum, as described previously (28). The markers were 
selected based on previously noted associations with endothe-
lial cell activation, endothelial dysfunction, or inflammation and/or 
juvenile DM pathogenesis.
Statistical analysis. Statistical analyses were performed 
using GraphPad Prism version 7.0, SPSS version 21 (IBM), or 
R version 3.5.1 (CRAN). Values below the detection limit were 
imputed as being 0.5 times the lowest measured value. For 
Spearman’s rank correlation (rs) analysis, imputed values were 
excluded. Cutoff values for receiver operating characteristic 
(ROC) curves were based on the Youden’s index. For compari-
sons between 2 groups, the Mann- Whitney U test was used for 
continuous variables and the Fisher’s exact test was used for 
categorical variables, with correction for multiple comparisons 
based on the false discovery rate (FDR), where applicable. P val-
ues less than 0.05 or an FDR less than 0.05 were considered 
statistically significant.
For unsupervised clustering by principal component analysis 
(PCA) and heatmap analysis with hierarchical clustering (Euclid-
ian/Ward), data were mean- centered and scaled per marker. 
Five markers (plasminogen activator inhibitor 1, fibronectin, 
oncostatin M, E- selectin, and thrombomodulin) had >30% of val-
ues below the limit of detection and were therefore excluded from 
the clustering analyses. For time until reaching DFR, a Kaplan- 
Meier estimator (dichotomized at the median value) and Cox pro-
portional hazards model with log- transformed data were used, 
along with the log- rank test.
RESULTS
Patient characteristics. The median age of the patients in 
the discovery and validation cohorts was 5.1 years and 7.0 years, 
respectively (Table 1). The majority of patients in both cohorts were 
female, with a significantly higher frequency of female patients in 
the discovery cohort compared to the validation cohort (86.7% 
versus 62.1%; P = 0.039) and slightly higher frequency of white 
patients (77% versus 76%). Moreover, the majority of patients 
in each cohort were white (77% in the discovery cohort versus 
76% in the validation cohort). The duration of untreated disease 
was higher in the discovery cohort (median 5.9 months versus 
3.2 months in the validation cohort; P = 0.02), and treatment 
intensification was needed in 57% of the discovery cohort, com-
pared to 29% of the validation cohort (P = 0.038). Muscle disease 
activity was similar in both cohorts (median CMAS 33 in each). 
Muscle enzyme levels were higher in the validation cohort.
In both cohorts, MSAs were detected in ~50% of patients. 
Although none of the MSAs differed significantly in their fre-
quency, anti–transcription intermediary factor 1γ (anti–TIF- 1γ) 
and anti–Mi- 2 antibodies were more frequent in the discovery 
cohort compared to the validation cohort (for anti–TIF- 1γ, 30% 
versus 14%; for anti–Mi- 2, 10% versus 0%), whereas anti–
nuclear matrix protein 2 (anti–NXP- 2) and anti–small ubiquitin- 
like modifier- 1 activating enzyme (anti–SAE- 1) antibodies 
were more frequent in the validation cohort compared to the 
discovery cohort (for anti–NXP- 2, 17% versus 7%; for anti–
SAE- 1, 7% versus 0%). The frequency of anti–melanoma dif-
ferentiation–associated protein 5 (anti–MDA- 5) antibodies was 
equal in both cohorts (each 7%), despite a higher frequency 
of children with an Asian background in the validation cohort. 
The initial treatment that was started after diagnosis was similar 
between the cohorts (Table 1).
Association between biomarker profiles and mus-
cle disease activity. To investigate the heterogeneity of bio-
marker profiles in treatment- naive juvenile DM patients, we 
performed unsupervised hierarchical clustering in the discovery 
cohort, which led to splitting the patients into 2 distinct clusters, 
comprising 8 patients (cluster 1) and 22 patients (cluster 2). Com-
pared to the larger cluster (cluster 2), the smaller cluster (cluster 1) 
stood out because of the patients’ significantly higher serum lev-
els of CXCL13, CCL19, galectin- 9 (Gal- 9), tumor necrosis factor 
receptor type II (TNFRII), Gal- 1, CXCL10, CXCL9, interleukin- 18 
(IL- 18), chitinase- 3–like protein 1 (YKL- 40), CCL2, CCL4, vas-
cular endothelial growth factor (VEGF), E- selectin, intercellular 
adhesion molecule 1 (ICAM- 1), and CCL18 and the patients’ 
significantly lower serum levels of fetuin (FDR <0.05) (Figures 1A 
and B).
To assess whether distinct biomarker profiles corresponded 
to specific clinical profiles, we compared disease character-
istics between the clusters (Figure  1C). Total disease activity 
(median DAS- T score) was significantly higher in cluster 1 than 
in cluster 2 (P = 0.0265), which was attributable to significantly 
higher muscle disease activity in cluster 1 (median DAS- M score, 
P = 0.0486; median CMAS score, P = 0.011) (Figure 1C). Skin dis-
ease activity scores and creatine kinase levels in the muscle were 
comparable, but patients in cluster 1 had higher lactate dehydro-
genase (LDH) levels in the muscle (P = 0.0285).
Multidimensional PCA identified muscle disease activity as 
an important factor explaining the variance in biomarker profiles, 
and confirmed that patients with the highest DAS- M score spa-
tially overlapped with cluster 1 (Figure 1D). ERL scores were sim-
ilar between the clusters. Levels of 12 of the 16 biomarkers that 
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were differentially expressed between the clusters correlated with 
the DAS- T, DAS- M, or CMAS scores. These included CXCL13, 
CCL19, Gal- 9, TNFRII, Gal- 1, CXCL10, CXCL9, IL- 18, YKL- 40, 
CCL2, CCL4, and ICAM- 1 (|rs| = 0.35–0.67, P < 0.05) (Table 2). 
High serum levels of these markers may therefore identify a sub-
group of patients with more severe disease.
Association of biomarker profiles with vascu­
lopathy. We next assessed which of the 39 markers showed 
a direct correlation with ERL scores (discovery cohort, n = 29). 
ERL scores correlated negatively with the serum levels of 
endoglin (rs = −0.67, P < 0.0001) as well as thrombospon-
din- 1 (TSP- 1) and VEGF (each rs = −0.415, P = 0.0252), and 
Figure 1. Association of heterogeneous biomarker profiles with differences in clinical disease activity in patients with juvenile dermatomyositis 
(DM). A panel of biomarkers for endothelial dysfunction and inflammation was measured by multiplex assay in the serum of 30 treatment- naive 
juvenile DM patients (discovery cohort). A, Unsupervised hierarchical clustering (by Euclidian distance and Ward’s method) of 30 patients in 
the discovery cohort based on serum levels of 34 biomarkers (mean- centered and scaled values) yielded 2 distinct patient clusters (clusters 
1 and 2). Values at the bottom represent unique patient identifiers (not ranked). B, Serum levels of the 6 markers most significantly different 
between cluster 1 (n = 8) and cluster 2 (n = 22) were compared by Mann- Whitney U test, with correction for multiple comparisons based on 
the false discovery rate. Symbols represent individual patients; horizontal lines show the median. C, Clinical scores for global Disease Activity 
Score (DAS- T), skin Disease Activity Score (DAS- S), muscle Disease Activity Score (DAS- M), Childhood Myositis Assessment Scale (CMAS) 
score, and muscle enzyme levels (creatine kinase [CK] and lactate dehydrogenase [LDH]) were compared between the 2 clusters. P values 
were determined by Mann- Whitney U test. Results are shown as box plots, where the boxes represent the 25th to 75th percentiles, the lines 
within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles. D, Principal components (PC1 
and PC2) analysis based on the 34 mean- centered markers shows patients stratified by cluster, DAS- S scores, and DAS- M scores. Circles 
with different colors represent clusters 1 and 2 or ranges of DAS- S and DAS- M scores. Closed circles represent individual patients, while open 
circles represent cluster centers. VEGF = vascular endothelial growth factor; Gal- 1 = galectin- 1; TNFRII = tumor necrosis factor receptor type 
II; YKL- 40 = chitinase- 3–like protein 1; IL- 18 = interleukin- 18; ICAM- 1 = intercellular adhesion molecule 1; VCAM- 1 = vascular cell adhesion 
molecule 1; SAA 1 = serum amyloid A 1; Ang- 2 = angiopoietin- 2; PIGF = placental growth factor; sVEGFR1 = soluble VEGF receptor 1; OSF- 2 = 
periostin; TWEAK = TNF- related weak inducer of apoptosis; C- TACK = cutaneous T cell–attracting chemokine; SPARC = secreted protein 
acidic and rich in cysteine; P- sel = P- selectin; Tie- 2 = angiopoeitin- 1 receptor; PDGF- BB = platelet- derived growth factor BB; TSP- 1 = 
thrombospondin- 1.
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 correlated positively with the serum levels of ICAM- 1 (rs = 0.465, 
P = 0.0111) (Figure  2A). Patients with an ERL score of <4, 
indicating severe vasculopathy, had significantly higher serum 
endoglin levels and lower serum ICAM- 1 levels compared to 
patients with an ERL score of ≥4 (P = 0.012 and P = 0.0079, 
respectively) (Figure 2B).
With regard to serum levels of endoglin, the area under the 
ROC curve (AUC) for identifying patients with low ERL scores 
(indicative of severe vasculopathy) relative to high ERL scores was 
0.771 (P = 0.0129). An optimal cutoff value of 2,286 pg/ml for 
the endoglin level yielded a sensitivity of 85.7% and specificity of 
73.3% for identifying patients with a low ERL score. With regard 
to serum levels of ICAM- 1, the AUC for identifying patients with 
a low ERL score was 0.786 (P = 0.0088), and a cutoff value of 
386,425 pg/ml yielded a sensitivity of 85.7% and specificity of 
80%. The combination of the 2 markers in a prediction model 
improved the AUC to 0.833 (P = 0.0023), but did not yield a higher 
sensitivity (79%) or specificity (80%) than that with ICAM- 1 alone. 
The presence of low serum levels of ICAM- 1 (and/or high serum 
levels of endoglin) may thus be suitable to identify patients with 
severe vasculopathy.
Validation of biomarker and clinical profiles in an 
independent cohort. To validate the association between 
biomarker profiles and clinical disease, the same biomarker 
panel was measured in an independent validation cohort of 
patients with juvenile DM (n = 29). The 16 markers that iden-
tified patients with severe (muscle) disease activity in the dis-
covery cohort were again assessed for correlations with 
clinical disease activity in the validation cohort. Four markers 
correlated significantly with clinical disease activity in both 
the discovery and validation cohorts: Gal- 9, TNFRII, Gal- 1, 
and CXCL10 (rs = 0.40–0.52 for correlations with the DAS- T 
and PhGA scores) (Table  2 and Figures  3A–D). Recipro-
cal analysis of the 2 cohorts using the same criteria, i.e., 1) 
clustering of the validation cohort by all markers, 2) selection 
of markers identifying the more severely affected cluster, and 3) 
subsequent assessment of correlations with clinical disease 
parameters, yielded the same 4 markers (Gal- 9, TNFRII, Gal- 1, 
and CXCL10), as well as soluble VEGF receptor 1 (sVEGFR- 1) 
(Table 2). Since sVEGFR- 1 was not one of the markers identify-
ing cluster 1 in the discovery cohort, it was not included as an 
additional marker in subsequent analyses.
Table  2. Spearman’s rank correlations of serum biomarker levels with clinical 
disease activity scores in juvenile dermatomyositis patients in the discovery and 
validation cohorts*
Discovery cohort Validation cohort
DAS- T 
(n = 30)
DAS- M 
(n = 30)
CMAS 
(n = 29)
PhGA 
(n = 25)
CMAS 
(n = 25)
CXCL13 0.538† 0.539† −0.476† NS NS
CCL19 0.541† 0.553† −0.497† NS NS
Gal- 9 0.519† 0.496† −0.428‡ 0.403‡ NS
TNFRII 0.518† 0.489† −0.377‡ 0.439‡ NS
Gal- 1 0.471† 0.495† NS 0.486‡ NS
CXCL10 0.505† 0.458‡ −0.397‡ 0.445‡ NS
CXCL9 0.432‡ NS NS NS NS
IL- 18 0.503† 0.415‡ −0.490† NS NS
YKL- 40 0.465† 0.524† −0.667§ NS NS
CCL2 0.557† 0.566† −0.532† NS NS
CCL4 0.388‡ NS −0.396‡ NS NS
VEGF NS NS NS NS NS
E- selectin NS NS NS NS NS
ICAM- 1 NS NS −0.515† NS NS
Fetuin NS NS NS NS NS
CCL18 NS NS NS NS NS
sVEGFR- 1¶ 0.422‡ 0.427‡ NS NS −0.454‡
* Spearman’s rank correlation coefficients are shown for those biomarkers whose 
serum levels were significantly different between cluster 1 and cluster 2. For 
biomarkers with out-of-range values (i.e., below the detection limit), the values 
were imputed (for CXCL9 and E- selectin), and imputed values were excluded from 
the analysis to prevent skewing of the data. DAS- T = Disease Activity Score for total 
disease activity; DAS- M = Disease Activity Score for the muscle; CMAS = Childhood 
Myositis Assessment Scale; PhGA = physician’s global assessment of disease activity; 
NS = not significant; Gal- 9 = galectin- 9; TNFRII = tumor necrosis factor receptor 
type II; IL- 18 = interleukin- 18; YKL-40 = chitinase 3–like protein 1; VEGF = vascular 
endothelial growth factor; ICAM- 1 = intercellular adhesion molecule 1. 
† P < 0.01. 
‡ P < 0.05. 
§ P < 0.0001. 
¶ This marker, soluble VEGF receptor 1 (sVEGFR- 1), only identifies patients in cluster 
1 in the validation cohort, but not in the discovery cohort. 
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We next examined whether these 4 markers would be able 
and sufficient to identify severely affected patients. Hierarchical 
clustering of the 2 cohorts based on these 4 markers yielded 2 
distinct patient clusters in each cohort (clusters of 9 patients and 
21 patients in the discovery cohort, and clusters of 6 patients and 
23 patients in the validation cohort) (Figures 3E and F). Indeed, 
in both cohorts, the smaller subgroup of patients with high lev-
els of Gal- 9, TNFRII, Gal- 1, and CXCL10 (cluster 1D and cluster 
1V from the discovery and validation cohorts, respectively) had 
significantly higher total disease activity and muscle disease activ-
ity scores compared to patients in cluster 2. Patients in cluster 
1D had higher DAS- T scores (P = 0.0078), higher DAS- M scores 
(P = 0.0181), and lower CMAS scores (P = 0.0148) compared to 
patients in cluster 2D, and patients in cluster 1V had higher PhGA 
scores (P = 0.0013) and lower CMAS scores (P = 0.0053) com-
pared to patients in cluster 2V (Figures 3G and H). Skin disease 
activity did not differ between the clusters in the discovery cohort, 
but in the validation cohort, skin disease activity (CAT score) was 
significantly higher in cluster 1V than in cluster 2V (P = 0.0131). In 
both cohorts, LDH levels were higher in cluster 1 than in cluster 
2 (P < 0.05 in each cohort). Thus, the combination of high serum 
levels of Gal- 9, TNFRII, Gal- 1, and CXCL10 may be sufficient to 
identify a subgroup of patients with severe global and muscle dis-
ease.
To assess the potency of each individual marker for identify-
ing severely affected patients, patients were stratified into severe 
disease (those in the >75th percentile of PhGA, DAS- T, and 
DAS- M scores or those in the <25th percentile of CMAS scores) 
and nonsevere (muscle or global) disease, and the AUCs of the 
ROC curves were determined for each marker. TNFRII had the 
highest AUC for identifying patients with severe muscle disease 
(AUC 0.80) and severe global disease (AUC 0.73), with a sensi-
tivity of 80% and 69% and specificity of 82% and 76%, respec-
tively, at a cutoff level of 3,010 pg/ml for levels of TNFRII. Due 
to the high correlations between the markers (rs = 0.76–0.95), a 
combined model with these markers was not constructed. There-
fore, it can be concluded that high serum levels of Gal- 9, TNFRII, 
Gal- 1, and CXCL10 can identify severely affected patients at the 
time of diagnosis, with TNFRII being the best indicator of severe 
disease.
Association of biomarker profiles with MSAs. Since 
MSA serotypes were previously linked to disease phenotypes, 
including (muscle) disease severity (7,8), we compared the fre-
quencies of MSAs (according to MSA category) between the 
biomarker- based clusters. The cohorts were combined into a sin-
gle cohort to yield a sufficient number of patients per MSA cate-
gory. Clustering by Gal- 9, CXCL10, TNFRII, and Gal- 1 expression 
produced 2 clusters of patients (combined cohort clusters 1C and 
2C) (Figure 4A).
Although none of the MSAs differed significantly in frequency 
between these 2 clusters, MSA- negative patients were rela-
tively more frequent in cluster 2C than in cluster 1C (57% versus 
35%) (Figures 4A and B). Frequencies of patients with anti–TIF- 1γ 
antibodies were similar between the clusters (21% in cluster 1C 
and 23% in cluster 2C). The numbers of patients with anti–SAE- 1, 
anti–Mi- 2, anti–NXP- 2, and anti–MDA- 5 antibodies were too small 
to statistically compare their frequencies between clusters, but it 
was notable that all 4 patients with anti–MDA- 5 autoantibodies 
were in cluster 2C. Moreover, all patients with strong expression 
of anti–NXP- 2 antibodies were in cluster 1C, whereas patients 
with weak anti–NXP- 2 expression were present only in clus-
ter 2C. Since weak antibody positivity may sometimes  indicate 
a  false- positive measurement, this might imply a difference in 
Figure 2. Correlation of biomarker levels with end row loop (ERL) 
scores. A panel of biomarkers for endothelial dysfunction and 
inflammation was measured by multiplex assay in the serum of 30 
treatment- naive juvenile dermatomyositis (DM) patients (discovery 
cohort). ERL scores (a count of ERLs/mm in the fingers, as a 
measure of the severity of vasculopathy) were assessed by nailfold 
capillaroscopy. A, Spearman’s rank correlations (rs) were determined 
to assess the correlation between serum biomarker levels and ERL 
scores in 29 juvenile DM patients. B, Serum levels of endoglin and 
soluble intercellular adhesion molecule 1 (sICAM- 1) were assessed in 
juvenile DM patients stratified according to low ERL scores (defined 
as <4) and high ERL scores (defined as ≥4). Symbols represent 
individual patients; horizontal lines show the median. Values above 
the graphs are P values, determined by Mann- Whitney U test. TSP- 
1 = thrombospondin- 1; VEGF = vascular endothelial growth factor.
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anti–NXP- 2 frequencies between cluster 1C and cluster 2C. The 
findings thus suggest that MSA serotypes were not directly linked 
to the biomarker- based patient clusters, but that patients with 
strong anti–NXP- 2 positivity may be more likely to be in the severe 
disease cluster, characterized by high biomarker levels, whereas 
the opposite may be true for patients with anti–MDA- 5 antibodies.
Prognostic value of biomarkers for suboptimal response 
to initial treatment. We next assessed whether high serum 
levels of Gal- 9, CXCL10, TNFRII, and/or Gal- 1 could be prog-
nostic for a suboptimal response to initial treatment. The fre-
quency at which intensification of treatment was required within 
the first 3 months after diagnosis was significantly higher in 
Figure 3. Identification of galectin- 9 (Gal- 9), tumor necrosis factor receptor type II (TNFRII), CXCL10, and Gal- 1 as biomarkers for stratification 
of patients with severe juvenile dermatomyositis (DM). A panel of biomarkers for endothelial dysfunction and inflammation was measured by 
multiplex assay in the serum of 59 treatment- naive juvenile DM patients. A–D, Spearman’s rank correlations (rs) were determined to assess the 
correlations of serum levels of Gal- 9 (A), TNFRII (B), CXCL10 (C), and Gal- 1 (D) with global disease activity as measured by the global Disease 
Activity Score (DAS- T) in the discovery (D) cohort and the physician’s global assessment of disease activity (PhGA) in the validation (V) cohort. 
* = P < 0.05; ** = P < 0.01. E and F, Unsupervised hierarchical clustering of juvenile DM patients in the discovery cohort (E) and validation 
cohort (F) was performed according to the normalized serum expression values for Gal- 9, TNFRII, CXCL10, and Gal- 1. Values at the bottom 
represent unique patient identifiers (not ranked). G and H, Clinical measures of disease activity were compared between cluster 1 and cluster 
2 (the same clusters as identified in E and F) in the discovery cohort (G) and validation cohort (H). Results are shown as box plots, where the 
boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th 
and 90th percentiles. Values above the graphs are P values, determined by Mann- Whitney U test. DAS- S = Disease Activity Score for the skin; 
DAS- M = Disease Activity Score for the muscle; CMAS = Childhood Myositis Assessment Scale (score); CK = creatine kinase; LDH = lactate 
dehydrogenase; CAT = cutaneous assessment tool for juvenile DM. Color figure can be viewed in the online issue, which is available at: http://
onlinelibrary.wiley.com/doi/10.1002/art.41236/abstract. 
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 cluster 1C than in cluster 2C (64.7% versus 34.1%; P = 0.0437) 
(Figure 4C), suggesting that, indeed, high biomarker levels may 
identify an “at risk” group of patients who might require intensifica-
tion of their initial treatment.
Although this combination of biomarkers could iden-
tify “at risk” patients, the individual biomarkers showed only a 
trend toward being higher in patients needing intensification of 
 treatment in the combined cohort (for CXCL10, P = 0.053; for 
Figure 4. Identification of galectin-1 (Gal-1), CXCL10, Gal-9, and tumor necrosis factor receptor type II (TNFRII) as biomarkers for patient 
stratification and for prognosis of response to therapy. A panel of biomarkers for endothelial dysfunction and inflammation was measured by 
multiplex assay in the serum of 59 treatment- naive juvenile dermatomyositis (DM) patients. A, Unsupervised hierarchical clustering of 59 juvenile 
DM patients in the discovery and validation cohorts combined (C) was performed according to the normalized serum expression values for Gal- 
9, CXCL10, TNFRII, and Gal- 1 and status of each myositis- specific antibody (MSA) serotype. The heatmap legend indicates the different MSA 
serotypes according to different colors. Values at the bottom represent unique patient identifiers (not ranked). B, Cumulative frequencies of MSA 
serotypes were compared between clusters 1C and 2C. P values for cluster 1C versus cluster 2C, as determined by chi- square test, were not 
significant (NS) for the MSA- negative and anti–transcription intermediary factor 1γ (anti–TIF1γ)–positive patients. C, Cumulative frequencies of 
patients needing intensification of treatment within the first 3 months after diagnosis were compared between cluster 1C and cluster 2C. Due 
to missing data on intensification of treatment for 1 patient in cluster 2C, the analysis was performed after exclusion of this patient. P values 
were determined by Fisher’s exact test. D, The capacity of serum levels of Gal- 9, CXCL10, TNFRII, and Gal- 1 to differentiate patients requiring 
intensification of treatment was assessed in the combined cohort and in the discovery (Disc) and validation (Val) cohorts separately. Results 
are shown as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the 
lines outside the boxes represent the 10th and 90th percentiles. Values above the graphs are P values, determined by Mann- Whitney U test. 
E, Cumulative frequencies of patients 1) with time to attainment of drug- free remission (DFR) of >4 years, 2) with time to attainment of DFR of 
<4 years, 3) who were still receiving medication at <4 years of follow- up (FU), or 4) whose medication use was unknown and who were lost to 
follow- up were compared between cluster 1C and cluster 2C. F, Kaplan- Meier curves show the months from diagnosis (Dx) until achievement of 
remission while not receiving immunosuppressive treatment among patients stratified according to the median serum levels of Gal- 9, CXCL10, 
Gal- 1, and TNFRII (high levels [n = 29] versus low levels [n = 30]). Shaded areas show the confidence intervals. Values below the plots are the 
number of patients at risk in the high- level (red) and low- level (blue) groups at each time point. P values were determined by log- rank test. Neg = 
negative; NXP- 2 = nuclear matrix protein 2; SAE- 1 = small ubiquitin- like modifier- 1 activating enzyme; MDA- 5 = melanoma differentiation–associated 
protein 5. Color figure can be viewed in the online issue, which is available athttp://onlinelibrary.wiley.com/doi/10.1002/art.41236/abstract.
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Gal- 1, P = 0.1097; for Gal- 9, P = 0.1783; for TNFRII, P = 0.1133) 
(Figure 4D). In the validation cohort, higher serum levels of Gal- 1 
and TNFRII potently identified patients needing intensification 
of treatment (for Gal- 1, P = 0.0057; for TNFRII, P = 0.0328) 
(Figure 4D). The results of the corresponding ROC curves are avail-
able from the corresponding author upon request. Again, due to 
the high correlation between the biomarkers, a combined model 
of these markers was not constructed. Thus, the combination of 
the 4 markers—Gal- 9, CXCL10, TNFRII, and Gal- 1—may iden-
tify patients who would be considered at risk for a suboptimal 
response to induction therapy.
Prognostic value of biomarkers for predicting time 
to attainment of DFR. Finally, we examined whether patients 
with high serum levels of Gal- 9, CXCL10, TNFRII, and/or Gal- 1 
at diagnosis would need a longer time to attain DFR. At the time 
of analysis, 24 (41%) of 59 patients had attained DFR (median 
follow- up time 4.0 years). Of the 10 patients in cluster 1C with 
a known time until DFR or with more than 4 years of follow- up, 
8 (80%) were still receiving medication after 4 years, whereas 
this was the case for only 7 (41%) of 17 patients in cluster 2C 
(P < 0.05) (Figure 4E).
Kaplan- Meier survival analysis with dichotomization of the 
single biomarkers into “high” and “low” serum levels according 
to the median values showed that patients with high serum levels 
of CXCL10, Gal- 9, or TNFRII at diagnosis needed a significantly 
longer time to attain DFR than patients with low biomarker levels 
(P < 0.05) (Figure 4F), although some cross- over of the Kaplan- 
Meier curves was evident, indicating that confounding factors may 
play a role, and the confidence intervals overlapped.
In Cox proportional hazards models, high biomarker levels 
showed a trend toward conferring a higher risk of “not getting 
off treatment” as compared to low biomarker levels (for Gal- 9, 
hazard ratio [HR] 0.32, P = 0.06; for TNFRII, HR 0.24, P = 0.08; 
for CXCL10, HR 0.39, P = 0.1; for Gal- 1, HR 0.41, P = 0.1). 
Patients with an ERL score of <4, indicating severe vasculopathy, 
also showed a trend toward needing longer time to attain DFR 
(Kaplan- Meier log- rank P = 0.069). Taken together, these results 
indicate that patients with high serum levels of Gal- 9, CXCL10, or 
TNFRII at diagnosis may be at risk for a longer disease course.
DISCUSSION
Herein we have shown that juvenile DM is a heterogeneous 
disease, not only in the clinical presentation, but also in the bio-
marker profiles at diagnosis. In 2 independent cohorts of patients 
with juvenile DM, we were able to identify a subgroup of patients, 
constituting approximately one- third of the study population, who 
exhibited high serum levels of Gal- 9, CXCL10, TNFRII, and Gal- 1 
and higher muscle and global disease activity, who were consid-
ered at risk of requiring intensification of initial treatment, and who 
experienced a longer time to reach DFR. These biomarkers could 
thus be used to identify a severely affected subgroup at diagnosis, 
and may be prognostic for the disease course. The biomarker- 
based clusters were not evidently correlated with MSA serotypes, 
but patients with strong anti–NXP- 2 positivity were more likely 
to be in the subgroup with high serum levels of Gal- 9, CXCL10, 
TNFRII, and Gal- 1 at diagnosis.
Our results are consistent with the findings from a study by 
Gitiaux et  al, in which approximately one- third of patients were 
identified as being severely affected (19). In our study, the severely 
affected subgroup of patients were not identified as having more 
severe vasculopathy based on their ERL scores. Moreover, the 
vasculopathy- associated biomarkers endoglin, ICAM- 1, TSP- 1, 
and VEGF did not aid in the identification of this subgroup. How-
ever, the observed correlations of VEGF and endoglin serum 
levels with severe vasculopathy are consistent with the findings 
of a recent study in which both proteins were shown to be up- 
regulated in lesions with active capillary injury in the muscle of 
patients with juvenile DM (7). Endoglin and VEGF were also found 
to be expressed in the muscle of patients with DM in other studies 
(29,30). Soluble endoglin has more widely been described as an 
antiangiogenic molecule and marker for vasculopathy (31). TSP- 1 
was previously suggested to be an antiangiogenic regulator (32) 
with a vasculopathic role in patients with juvenile DM (in particular, 
patients with the TNF- 308A allele) (33). We found a positive asso-
ciation between the serum ICAM- 1 levels and ERL scores in the 
present study. Since endothelial activation is one of the hallmarks of 
juvenile DM–associated vasculopathy (34), and soluble ICAM- 1 lev-
els are correlated with endothelial surface ICAM- 1 expression (35), 
this finding is difficult to explain in the context of the disease. Future 
studies may provide insights into the underlying biologic processes.
Two of the 4 identified severity markers, Gal- 9 and CXCL10, 
are known IFN- related proteins (36,37). The correlation between 
severe muscle disease activity and high levels of IFN- related mark-
ers or the IFN signature (in blood and biopsy samples) has been 
previously demonstrated in juvenile DM patients at the time of 
disease onset (13,38,39) and during follow- up (16). A higher IFN 
signature was also associated with a longer time to reach clinically 
inactive disease (39). The serum levels of Gal- 9, CXCL10, and 
TNFRII were shown to specifically correlate with muscle disease 
activity during follow- up in our cohorts of patients with juvenile 
DM, and Gal- 9 and CXCL10 serum levels were recently validated 
as biomarkers for disease activity in patients with juvenile DM 
(17,40). Moreover, patients experiencing a disease flare within the 
first year after the start of treatment had higher levels of Gal- 9 and 
CXCL10 at diagnosis (40). TNFRII levels were found to be high in 
adult DM patients with a high type I IFN score, and neutralization 
of the IFN signature by an anti- IFNα monoclonal antibody resulted 
in decreased levels of TNFRII, suggesting that TNFRII may also be 
related to IFN- driven inflammation (41).
The increased expression of circulating IFN- inducible proteins 
in severely affected patients further supports the pathogenic role 
of IFNs in juvenile DM immunopathology. Gal- 1 has not been pre-
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viously linked to DM, but degeneration of injured muscles induces 
high expression of Gal- 1, and its expression may increase muscle 
regeneration in experimental models (42,43). In addition, Gal- 1 is 
an antiviral effector molecule expressed by endothelial cells and 
a negative regulator of both T cell recruitment to the endothelium 
and transendothelial migration (44–46).
Consistent with our results indicating that muscle disease 
activity was more pronounced in the severely affected patient 
cluster, the anti–NXP- 2 antibody serotype was previously asso-
ciated with more severe muscle disease, whereas anti–MDA- 5–
positive patients were less likely to have muscle weakness (3). 
In contrast with the findings from previous studies, we did not 
observe high levels of IFN- related markers in patients with anti–
MDA- 5  antibodies (47).
As opposed to muscle disease activity, skin disease activity 
was not related to any of the markers or marker profiles in the 2 
cohorts. Possible explanations for this finding could be that skin 
disease activity showed relatively low variance across patients 
(mainly in the discovery cohort), or that muscle disease had a 
dominant effect on the biomarker profiles (as also suggested by 
the PCA plots in Figure 1D), which could overrule any moderate 
correlations with skin disease.
Whereas in the validation cohort, Gal- 1 and TNFRII serum 
levels were higher in patients requiring intensification of treatment, 
this was not the case in the discovery cohort. This difference could 
not be explained by differences in the initial treatment approach, 
as the approaches were similar between the cohorts. We could 
speculate that the standardized treatment regimen in the vali-
dation cohort (as opposed to the more individualized strategy 
employed in the discovery cohort) led to a homogeneous/well- 
defined group of patients receiving intensification of treatment—
with certain specific characteristics conforming to the applied 
protocol. This homogeneity could be reflected in their biomarker 
profiles. In addition, the difference may be related to the longer 
duration of untreated disease in the discovery cohort compared 
to the validation cohort.
Juvenile DM is a very rare disease, which hampers the col-
lection of large sample numbers for study purposes. A unique 
strength of our study is that we were able to perform biomarker 
profiling in 2 large (given the rarity of the disease), independent 
cohorts of treatment- naive patients. We were thereby able to 
analyze the unmodified disease signatures in different patients 
without possible treatment effects on biomarker profiles. Although 
the cohorts showed some differences in baseline characteristics 
(e.g., duration of untreated disease, MSA frequencies, require-
ment of treatment intensification, ethnicity), which could have 
conferred bias in their biomarker profiles, we were able to validate 
our findings, showing that Gal- 9, TNFRII, Gal- 1, and CXCL10 are 
robust markers for the identification of a subgroup of patients with 
severe disease, even in cohorts with different patient character-
istics. A limitation of this study is the difference in the methods 
used to record disease activity between the 2 cohorts, which 
was attributable to historical and regional differences in the data 
collection methods. However, the PhGA and DAS- T scores, as 
well as the CAT and DAS- S scores, have been shown to correlate 
strongly (48).
Further validation of these data in a large prospective cohort 
will allow for the construction of prediction models that could be 
used to predict those patients who will require intensification of 
treatment or to predict the length of time to attainment of DFR, 
possibly combining one or more of the biomarkers with clinical 
parameters (such as age at onset and clinical disease activity). 
We speculate that patients in the “at risk” group could benefit 
from more intensive monitoring during induction treatment in order 
to detect suboptimal response to therapy in an early phase. This 
early detection would promote a swift intensification of treatment. 
Future studies will have to point out whether more aggressive or 
targeted initial treatment (e.g., with JAK inhibition or anti- IFN anti-
bodies) could also be a treatment option in these patients (49,50). 
Considering the longer time to remission, it may be useful to 
discuss with patients and parents the expectations of treatment 
length and the possible effect on cumulative medication dose, as 
these may have implications for the long- term outcomes.
In conclusion, the results of this study underline the clinical 
and serologic heterogeneity of juvenile DM. Moreover, the iden-
tification of high serum levels of the biomarkers Gal- 9, TNFRII, 
CXCL10, and Gal- 1 in patients with juvenile DM would suggest 
that these markers may be useful tools for identifying severely 
affected patients who could be at risk of a suboptimal response to 
standard immunosuppressive treatment.
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